共 50 条
- [3] Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants [J]. FRONTIERS IN PEDIATRICS, 2024, 12
- [4] Viral respiratory burden in moderate-to-late preterm infants [J]. EARLY HUMAN DEVELOPMENT, 2013, 89 : S37 - S39
- [5] Respiratory syncytial virus risk factors in late preterm infants [J]. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2009, 22 : 102 - 107
- [8] Hospital admissions for bronchiolitis in preterm infants in the absence of respiratory syncytial virus prophylaxis [J]. ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2005, 90 (01): : F92 - F92